'It's time for change,' nurses call for removal of Wexner, Landon names at OSUMC

Les Wexner, the largest individual donor to Ohio State with personal gifts exceeding $200 million, faces renewed calls from the Ohio Nurses Association to remove Wexner and Abigail Wexner names from university and hospital facilities amid his past ties to Jeffrey Epstein; nurses also seek removal of Dr. Mark Landon’s name from a Labor & Delivery lobby while Ohio State investigates Landon after his appearance in documents related to Epstein. More than 300 formal requests to reconsider naming have been submitted under the university’s naming review procedure, protesters plan action at the new hospital tower opening, and Governor DeWine has publicly opposed removal — signaling reputational and governance risk for the institutions but limited direct financial or market impact.

Analysis

Market structure: This is a localized reputational shock concentrated on Ohio State and its hospital partner; winners are specialist ESG managers, crisis-insurance brokers and large diversified hospital systems that can pick up displaced referrals, while losers are the affected university hospital units, local fundraising pipelines and any counterparties to named-endowment contracts. Expect impacts to be measurable locally (patient/visitor sentiment could depress volumes by an estimated 0–3% for affected units over 3–12 months) but negligible for national healthcare revenue streams (<0.5% GDP-level effect).

Risk assessment: Tail risks include a trustees' forced renaming, class-action suits, or major donor withdrawal; each has low probability (<10% within 12 months) but high severity (>$50–200m in direct costs and lost fundraising). Timeframe: protests and headlines are immediate (days), board and naming reviews play out in weeks–months, legal/settlement tail risk unfolds over quarters–years. Hidden dependencies: university bond covenants, naming-right contracts, and insurer D&O coverage limits could transmit losses to banks/insurers.

Trade implications: Execute small, tactical positions: favor insurers/brokers expected to reprice D&O (e.g., MMC, AON) and large-cap hospital operators (HCA) that can capture incremental referrals; trim concentrated exposure to regional/small hospital operators (UHS, THC) that rely on local trust. Use option structures to size asymmetry: short-dated hedges around key catalysts (OSU board meetings in 30–90 days) and directional 3–6 month spreads to express conviction without large delta risk.

Contrarian angle: Consensus overstates systemic market damage and understates governance inertia — many boards avoid renaming without legal proof, so the controversy often burns out in 2–6 months. If no binding legal findings or removal decisions appear within 60 days, expect reputational risk premiums to compress 50–80% and a tactical rebound in underweighted regional healthcare names; conversely, a removal decision would be the binary re-rating event to act decisively.

Key Decisions for Investors

• Trim 1–2% of portfolio exposure to regional hospital operators UHS and THC within 30 days (reduce tail risk from local patient-volume and reputational pressure).
• Establish a 1.5–2% long allocation split 60/40 to MMC (Marsh & McLennan) and AON over the next 90 days to capture likely D&O/reputational risk repricing; target 6–12% IRR from increased premium flows over 12–24 months.
• Buy a 3‑month call spread on HCA (buy ATM, sell 10% OTM) sized to 1% notional to express upside if patients shift to larger systems; roll or unwind after 90–180 days depending on OSU board action.
• If the OSU Board votes to remove the Wexner name (trigger within 30–90 days), initiate a 2% short of hospital-reliant regional REITs (e.g., MPW if >20% hospital exposure) or increase shorts on UHS/THC; if no removal within 60 days and local patient metrics show <2% decline, add 1–2% back to UHS/THC (mean reversion trade).